[go: up one dir, main page]

EE04310B1 - Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine - Google Patents

Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine

Info

Publication number
EE04310B1
EE04310B1 EE9700283A EE9700283A EE04310B1 EE 04310 B1 EE04310 B1 EE 04310B1 EE 9700283 A EE9700283 A EE 9700283A EE 9700283 A EE9700283 A EE 9700283A EE 04310 B1 EE04310 B1 EE 04310B1
Authority
EE
Estonia
Prior art keywords
compounds
phenyl
disorders
pharmaceutical compositions
compositions containing
Prior art date
Application number
EE9700283A
Other languages
English (en)
Estonian (et)
Other versions
EE9700283A (et
Inventor
Teuber Lene
W�tjen Frank
Fukuda Yoshimasa
Ushiroda Osamu
Sasaki Toshiro
Original Assignee
Neurosearch A/S
Meiji Seika Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S, Meiji Seika Kaisha, Ltd. filed Critical Neurosearch A/S
Publication of EE9700283A publication Critical patent/EE9700283A/xx
Publication of EE04310B1 publication Critical patent/EE04310B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9700283A 1995-04-21 1996-04-17 Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine EE04310B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK46095 1995-04-21
PCT/EP1996/001606 WO1996033194A1 (fr) 1995-04-21 1996-04-17 Composes de benzimidazole et leur utilisation en tant que modulateurs du complexe de recepteurs gaba¿a?

Publications (2)

Publication Number Publication Date
EE9700283A EE9700283A (et) 1998-06-15
EE04310B1 true EE04310B1 (et) 2004-06-15

Family

ID=8093808

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700283A EE04310B1 (et) 1995-04-21 1996-04-17 Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine

Country Status (22)

Country Link
US (2) US5922724A (fr)
EP (3) EP0821684B1 (fr)
JP (2) JP3342874B2 (fr)
KR (2) KR100297445B1 (fr)
CN (2) CN1072669C (fr)
AT (2) ATE210132T1 (fr)
AU (2) AU695957B2 (fr)
BR (1) BR9608048A (fr)
CA (2) CA2218493C (fr)
CZ (1) CZ287545B6 (fr)
DE (2) DE69617665T2 (fr)
EE (1) EE04310B1 (fr)
HU (1) HUP9801692A3 (fr)
IS (1) IS1959B (fr)
NO (1) NO314504B1 (fr)
NZ (1) NZ307521A (fr)
PL (1) PL183853B1 (fr)
RU (1) RU2135493C1 (fr)
SK (1) SK282425B6 (fr)
TR (1) TR199701218T2 (fr)
UA (1) UA54393C2 (fr)
WO (2) WO1996033194A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726447B2 (en) * 1996-10-21 2000-11-09 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
GB9622370D0 (en) * 1996-10-28 1997-01-08 Merck Sharp & Dohme Therapeutic agents
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1126843A4 (fr) * 1998-10-29 2005-06-15 Bristol Myers Squibb Co Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
EP1132087A4 (fr) 1998-11-13 2002-06-26 Fujisawa Pharmaceutical Co Remedes contre le syndrome des ovaires polykystiques
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
ES2226812T3 (es) * 1999-04-02 2005-04-01 Neurogen Corporation Derivados de aminoalquilimidazol condensados con arilo y heteroarilo:moduladores selesctivos de los preseptores gabaa.
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
AU777961B2 (en) 1999-06-22 2004-11-04 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
EP1194152A4 (fr) * 1999-06-30 2002-11-06 Merck & Co Inc Composes inhibiteurs de la kinase src
CA2383546A1 (fr) 1999-06-30 2001-01-04 William H. Parsons Composes inhibiteurs de la src kinase
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP3790472B2 (ja) * 1999-08-19 2006-06-28 エヌピーエス ファーマシューティカルズ インコーポレーテッド ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0208394D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
US7329678B2 (en) * 2003-01-28 2008-02-12 Smithkline Beecham Corporation Chemical compounds
WO2004087137A1 (fr) 2003-04-03 2004-10-14 Neurosearch A/S Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa
JP2006522070A (ja) 2003-04-03 2006-09-28 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
WO2005040131A1 (fr) * 2003-10-23 2005-05-06 Akzo Nobel N.V. Derives de benzimidazole 1,5,7-trisubstitutes et leur utilisation pour la modulation du complexe recepteur gabaa
PT1877052E (pt) 2005-04-13 2009-08-25 Neurosearch As Derivados de benzimidazole e sua utilização para modulação do complexo do receptor gabaa
US20070015782A1 (en) * 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (fr) * 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
DK1996556T3 (da) 2005-12-05 2010-04-06 Neurosearch As Benzimidazoiderivater og deres anvendelse til modulering af GABAA-receptorkomplekset
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
EP2026813A2 (fr) 2006-05-09 2009-02-25 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
EP2430921B1 (fr) * 2007-04-03 2017-07-05 E. I. du Pont de Nemours and Company Fongicides de benzène substitués
US20100190826A1 (en) 2007-07-24 2010-07-29 Akio Kakefuda Benzimidazole derivative
KR20090024998A (ko) * 2007-09-05 2009-03-10 제일모직주식회사 분자 내에 정공수송기와 전자수송기를 동시에 가지는바이폴라 유기화합물을 포함하는 유기광전소자용 재료 및이를 이용한 유기광전소자
WO2010055126A1 (fr) * 2008-11-14 2010-05-20 Neurosearch A/S Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
EP2383573A4 (fr) 2009-01-27 2012-10-24 Astellas Pharma Inc Procédé de criblage de substance utile en tant qu'agent pour le cancer de la prostate
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US8754100B2 (en) * 2009-02-26 2014-06-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2011047315A1 (fr) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Benzimidazoles substitués
WO2014053409A1 (fr) * 2012-10-01 2014-04-10 F. Hoffmann-La Roche Ag Benzimidazoles en tant qu'agents actifs sur le snc
EP2935253B1 (fr) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3010918B1 (fr) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
CA2966298A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Pyridinones substituees utilisees comme inhibiteurs de bromodomaines
CA2966449A1 (fr) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Heterocycles substitues a titre d'inhibiteurs de bromodomaines
EP3233846A4 (fr) * 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibiteurs de bromodomaines
US11628159B2 (en) 2017-01-10 2023-04-18 Eth Zurich Cell-protective compounds and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000936A1 (fr) * 1978-04-17 1979-11-15 Basab Materialhantering Ab Dispositif de levage et de transport de marchandises
DE2853765A1 (de) * 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
PH30434A (en) * 1989-04-07 1997-05-09 Janssen Pharmaceutica Nv Hydroxyalkylfuranyl derivatives
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation

Also Published As

Publication number Publication date
JPH11501321A (ja) 1999-02-02
US5902813A (en) 1999-05-11
DE69617665D1 (de) 2002-01-17
DE69636670T2 (de) 2007-02-08
DE69636670D1 (de) 2006-12-14
JPH11501320A (ja) 1999-02-02
RU2135493C1 (ru) 1999-08-27
AU5689196A (en) 1996-11-07
CA2217601A1 (fr) 1996-10-24
AU695957B2 (en) 1998-08-27
UA54393C2 (uk) 2003-03-17
NO974844D0 (no) 1997-10-20
EP0821683B1 (fr) 2006-11-02
NO974844L (no) 1997-12-16
JP3040485B2 (ja) 2000-05-15
WO1996033194A1 (fr) 1996-10-24
EP0821684B1 (fr) 2001-12-05
WO1996033192A1 (fr) 1996-10-24
EE9700283A (et) 1998-06-15
NZ307521A (en) 1999-04-29
PL183853B1 (pl) 2002-07-31
KR100297445B1 (ko) 2001-10-25
HUP9801692A3 (en) 2001-11-28
CZ329297A3 (cs) 1998-03-18
NO314504B1 (no) 2003-03-31
ATE210132T1 (de) 2001-12-15
CN1182426A (zh) 1998-05-20
JP3342874B2 (ja) 2002-11-11
EP0821683A1 (fr) 1998-02-04
KR19990007942A (ko) 1999-01-25
CN1072669C (zh) 2001-10-10
DE69617665T2 (de) 2002-05-08
HUP9801692A2 (hu) 1999-03-29
CN1182427A (zh) 1998-05-20
EP1164134A1 (fr) 2001-12-19
US5922724A (en) 1999-07-13
BR9608048A (pt) 1999-11-30
EP0821684A1 (fr) 1998-02-04
SK282425B6 (sk) 2002-01-07
CA2217601C (fr) 2002-04-16
TR199701218T2 (xx) 1998-08-21
KR19990007941A (ko) 1999-01-25
HK1015674A1 (en) 1999-10-22
CA2218493C (fr) 2005-02-22
CA2218493A1 (fr) 1996-10-24
SK139997A3 (en) 1998-05-06
ATE344257T1 (de) 2006-11-15
IS4588A (is) 1997-10-13
PL322892A1 (en) 1998-03-02
AU5501496A (en) 1996-11-07
IS1959B (is) 2004-11-15
CZ287545B6 (en) 2000-12-13

Similar Documents

Publication Publication Date Title
EE04310B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
EE04308B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
FI904327A0 (fi) N-substituerad-4-pyrimidinaminer och -pyrimidindiaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ES2117795T3 (es) Derivados de acetamida y su uso como modificadores del comportamiento de toma alimentaria.
NO964698D0 (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
SE8802412L (sv) Tiokarbamidderivat
DK1242406T3 (da) Hidtil ukendte forbindelser
ATE412628T1 (de) N- (1-dimethylaminocycloalkyl)methyl benzamid- derivate
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
MX9203939A (es) Derivados de hidroisoquinolina y composiciones farmaceuticas que los contienen.
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ATE171939T1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
ATE266026T1 (de) Benzofurancarboxamide und deren therapeutische verwendung
ATE31059T1 (de) N-(arylpropyl)-azolylharnstoffe und diese enthaltende fungizide.
MX9708096A (es) Compuestos de bencimidazol y su uso para preparar composiciones utiles como moduladores del complejo receptor de gabaa.
KR910000143A (ko) 간질치료제로서의 5-페닐-2- 푸란 에스테르 및 아미드의 용도
TH19682A (th) สารประกอบ 5-(2-อิมิตาโซลินิลอะมิโน) เบนซิมิดาโซล ที่ใช้เป็นประโยชน์เป็นสิ่งกระตุ้นอวัยวะสัมผัสแอลฟา-2

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

MM4A Lapsed by not paying the annual fees

Effective date: 20070417